Carregant...
Predicting Bevirimat resistance of HIV-1 from genotype
BACKGROUND: Maturation inhibitors are a new class of antiretroviral drugs. Bevirimat (BVM) was the first substance in this class of inhibitors entering clinical trials. While the inhibitory function of BVM is well established, the molecular mechanisms of action and resistance are not well understood...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3224585/ https://ncbi.nlm.nih.gov/pubmed/20089140 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2105-11-37 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|